BrdU Labeled Nucleotide Triphosphates for Non-Isotopic In Situ Hybridization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in situ hybridization methods, particularly isotopic techniques, are time-consuming and pose safety risks due to the use of radioisotopes, whereas non-isotopic methods lack sensitivity and efficiency in detecting specific DNA or RNA sequences in tissue samples.
Innovation Solution
Development of non-radioactive nucleotide probes, such as 5-bromo-2'-deoxyuridine (BrdU) labeled nucleotides, which are incorporated into polynucleotides and used in conjunction with anti-BrdU antibodies for detection, allowing for sensitive and efficient localization of nucleic acid analytes in tissue samples without the need for radioactive materials.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If isotopic in situ hybridization is used, then detection sensitivity is improved, but safety risks and complexity increase due to radioisotope handling
Solution Approach 1:
The patent introduces a non-radioactive intermediary system consisting of BrdU-labeled nucleotides and anti-BrdU antibodies conjugated to detectable moieties (enzymes, fluorophores, or colloidal gold). This intermediary system replaces direct radioactive labeling while maintaining detection sensitivity through the specific antigen-antibody interaction, thereby eliminating safety risks associated with radioisotopes.
2Productivity
If non-isotopic in situ hybridization is used, then safety and speed are improved, but detection sensitivity decreases
Solution Approach 1:
The patent employs parameter changes by modifying the detection system from direct radioactive signal to a multi-component non-radioactive signal amplification system. The anti-BrdU antibody conjugated to enzymes (e.g., alkaline phosphatase) or fluorophores provides enhanced signal intensity, allowing non-isotopic methods to achieve sensitivity comparable to or exceeding isotopic methods while maintaining faster procedure times.
3Productivity
If BrdU labeled probes are used, then safety and procedure time are improved, but manufacturing complexity increases due to multiple components
Solution Approach 1:
The patent merges multiple functions into integrated components: the anti-BrdU antibody is conjugated directly to detectable moieties (enzymes, fluorophores, or colloidal gold) to create a single reagent that performs both detection and signal generation. This consolidation simplifies the overall system while maintaining the advantages of non-isotopic methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The BrdU labeled probes provide a safer, quicker, and more sensitive means to detect nucleic acid analytes, avoiding the disadvantages of radioactive isotopes and enabling effective visualization of gene expression in heterogeneous cell populations.
Implementation Method 1
contacting the sample with an anti-BrdU antibody conjugated to a detectable moiety or to an enzyme; and detecting the detectable moiety or enzyme
Data Source
Figure 1
Figure 2
AI summary
5-bromo-2'-deoxy-uridine (BrdU) labeled nucleotide triphosphates and nucleic acid probes are described herein. The BrdU labeled nucleotide triphosphates include a linker between the nucleotide triphosphate and the BrdU moiety. The linker can be cleavable or non-cleavable. The nucleotide triphosphates can be a ribonucleotide triphosphates, 2'-deoxyribonucleotide triphosphates or 2',3 '-dideoxyribonucleotide triphosphates. The nucleic acid probes can be used for in situ hybridization.